Incorporating HIV/HCV Prevention, Screening, and Linkage to Care Into Opioid Use Disorder Treatment Settings

In this downloadable slideset, CCO’s expert faculty reviews important strategies for expanding addiction medicine services to include prevention, screening, diagnosis, and linkage to HCV and HIV care for patients with opioid use disorder.
Alain H. Litwin, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.42 MB
Released: September 18, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Produced in collaboration with
American Society of Addiction Medicine
Educational grant provided by:
Gilead Sciences

Related Content

CCO commentary by Dr. Jenna Butner on the importance of and strategies for incorporating HIV risk counseling into substance use disorder care

Jenna Butner, MD Released: August 24, 2020

Expert guidance on screening and medication treatment for opioid use disorder (OUD) in HIV and other infectious disease practice settings, from CCO

Sandra Springer, MD Released: June 25, 2020

Downloadable PDF resource from CCO on opioid use disorder treatment essentials for hepatologists and ID specialists managing HCV and/or HIV infection

Jenna Butner, MD Released: May 7, 2020

Latest data and best practice guidance on treating HCV in addiction medicine settings published by Clinical Care Options (CCO)

Andrew Seaman, MD Released: February 24, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue